Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2022-05-09 Annual Report
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
04_BOTHE_AR2021_EN_vFinal.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'FINANCIAL REPORT 2021' and contains a comprehensive table of contents covering business overview, corporate governance, remuneration, consolidated financial statements, and statutory accounts for the fiscal year ending 31 December 2021. It is clearly the full annual report of Bone Therapeutics SA, not an announcement or a summary. FY 2021
2022-05-09 English
04_BOTHE_AR2021_FR_vFinal.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'RAPPORT FINANCIER 2021' and contains a comprehensive table of contents covering the Board of Directors' report, corporate governance, financial statements (IFRS), notes to the financial statements, and the auditor's report for the fiscal year ending December 31, 2021. This structure is characteristic of a full Annual Report (10-K equivalent). FY 2021
2022-05-09 French
03_BOTHE_EGM_20220608_Information shareholders rights_EN_vFinal.pdf
AGM Information Classification · 98% confidence The document explicitly discusses the rights of shareholders concerning an upcoming 'EXTRAORDINARY GENERAL MEETING OF THE COMPANY TO BE HELD ON 8 JUNE 2022'. It details procedures for shareholders to include items on the agenda, submit proposals, and ask written questions prior to the meeting, referencing specific articles of the Belgian Company Code (7:130 and 7:139). This content is directly related to the preparation and execution of a shareholder meeting, which aligns perfectly with the definition of AGM Information (AGM-R) or Proxy Solicitation & Information Statement (PSI). Since the document focuses heavily on the procedural rights related to the meeting agenda and voting/question submission, it is most accurately classified as AGM Information (AGM-R), which covers presentations and materials shared during the AGM, or materials leading up to it concerning shareholder rights. Given the focus on shareholder rights regarding agenda items and questions for the EGM, AGM-R is the most precise fit over PSI, which usually refers to the formal proxy statement itself. The document is not a formal proxy statement (DEF 14A) or a declaration of voting results (DVA), but rather the notice detailing how shareholders can influence the meeting.
2022-05-09 English
01_BOTHE_EGM-20220608_Convening notice_FR_vFinal.pdf
AGM Information Classification · 100% confidence The document is explicitly titled "CONVOCATION À L'ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE QUI SE TIENDRA LE 8 JUIN 2022" (Notice of Extraordinary General Meeting to be held on June 8, 2022). It details the agenda, quorum requirements, voting procedures, and conditions for shareholder participation in a general meeting. This content directly corresponds to the definition of materials shared during an Annual General Meeting (AGM) or related preparatory/notice documents. The appropriate code is AGM-R.
2022-05-09 French
02_BOTHE_EGM-20220608_Proxy form_EN_vFinal.pdf
Proxy Solicitation & Information Statement Classification · 99% confidence The document is explicitly titled "PROXY FORM" and details the process for a shareholder to appoint a representative (proxy holder) to vote on their behalf at an "extraordinary general meeting of Bone Therapeutics S.A." scheduled for June 8, 2022. It includes sections for shareholder details, proxy appointment, the agenda (including resolutions on capital renewal and registered office transfer), voting instructions, and quorum requirements. This material is directly related to soliciting shareholder votes and providing information for that purpose, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement.
2022-05-09 English
03_BOTHE_EGM_20220608_Information droits actionnaires_FR_vFinal.pdf
AGM Information Classification · 98% confidence The document explicitly details shareholder rights concerning an upcoming Extraordinary General Meeting (Assemblée Générale Extraordinaire) scheduled for June 8, 2022. It covers procedures for shareholders to add items to the agenda (Article 7:130) and the right to submit written questions prior to the meeting (Article 7:139). This content is directly related to the preparation and conduct of a shareholder meeting, specifically focusing on proxy materials, voting rights, and shareholder participation rules. This aligns best with the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings, or potentially AGM-R if it were the actual meeting materials, but since it details the *rights* leading up to the meeting, PSI is a strong fit, although AGM-R is also plausible as it relates to the AGM. Given the focus on shareholder rights regarding agenda setting and questions, which are core components of proxy materials and meeting notices, PSI is the most precise fit among the options provided, as it precedes the actual meeting presentation (AGM-R).
2022-05-09 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.